Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
  
Rebecca Cheung, PharmD
Vice Chair, Pharmacy Practice
School of Pharmacy
Associate Professor, Pharmacy Practice
School of Pharmacy
Publications    Scholarly Journals--Published
  • Cheung RJ, Nguyen SK. Aspirin and clopidogrel resistance: is there a role for platelet function tests? CJHP 2008;20:16-21.

    ( 0/2008 )
  • Chow SL and Cheung RJ. Aspirin resistance: a growing concern. Formulary 2006 431:192-201.

    ( 0/2006 )
  • Ito MK, Cheung RJ, Gupta EK, Bircher KK, Chong PH, Bianco TM, Bleske BE. Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias - 2005. Pharmacotherapy 2006;26:939-1010.

    ( 0/2006 )
  • Patel S, Roshan V, Lee KC, Cheung RJ. A myoclonic reaction with low-dose hydromorphone. Ann Pharmacother 2006;40:2068-70.

    ( 0/2006 )
  • Cheung RJ, Gupta EK, Ito MK. Acute coffee ingestion does not affect LDL cholesterol level. Ann Pharmacother 2005;39:1209-13l.

    ( 0/2005 )
  • Cheung RJ and Ito MK. Clinical utility of extended-release niacin: update and summary. Future Cardiol 2005;1:571-8.

    ( 0/2005 )
  • Chiong J R, & Cheung R J. (2013). Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry?. Korean Circ J, 43(5), 287-92. ( 5/2013 - Present ) Link...
    BACKGROUND AND OBJECTIVES: The prevalence of atrial fibrillation (AF) doubles in the extreme elderly and is higher than in the rest of the population. Warfarin therapy to prevent thromboembolic events secondary to AF is often underutilized and under-prescribed in this subgroup, due to the fear of bleeding and other complications. Newer oral anticoagulants such as rivaroxaban and dabigatran offer alternative therapeutic options for the extreme elderly. We review the clinical trial data of these newer agents in the extreme elderly population. SUBJECTS AND METHODS: THE PRIMARY LITERATURE WAS IDENTIFIED THROUGH PUBMED, USING THE FOLLOWING SEARCH TERMS: anticoagulation, rivaroxaban, dabigatran, warfarin, elderly, AF, bleeding, stroke, and aging. Additional references were identified through the review of references from the articles obtained. We included clinical studies evaluating anticoagulation therapies in AF. Selection emphasis was placed on those evaluating anticoagulation in the elderly population. RESULTS: Dabigatran and rivaroxaban have predictable, dose-proportional pharmacokinetic and pharmacodynamic properties, which make them favorable options for the elderly. Fewer monitoring parameters and drug interactions allow for the greater ease of use. A landmark trial shows that the rate of intracranial hemorrhage with dabigatran is lower in this population compared to warfarin. However, the data is based on a small number of subjects enrolled in the clinical trials. As such, the real-world use of these agents may not replicate the published rates of bleeding and thrombosis in the study populations. CONCLUSION: More research is needed in this area, specifically in this population, before newer agents such as rivaroxaban and dabigatran are widely recommended for use in the extreme elderly patients.
  • Chiong J R, & Cheung R J. (2010). Loop Diuretic Therapy in Heart Failure: The Need for Solid Evidence on a Fluid Issue. Clinical Cardiology, 33(6), 345-352. ( 6/2010 - Present ) Link...
    Background: Heart failure (HF) is a common condition associated with substantial cost, morbidity, and mortality. Because results of clinical trials in the acute decompensated heart failure (ADHF) setting have been mostly neutral, loop diuretics remain the mainstay of treatment. Hypothesis: Loop diuretic use may be associated with unfavorable outcomes. Methods: A MEDLINE literature search was performed to identify articles relating to heart failure and loop diuretics. The current evidence on the risks and benefits of loop diuretics for the treatment of ADHF is reviewed. Results: Loop diuretics are associated with symptomatic improvements in congestion, urine output, and body weight, but have shown no long-term mortality benefit. Loop diuretics, especially at high doses, are associated with worsened renal function and other poor outcomes. Conclusions: Loop diuretics still prove useful in HF treatment, but risk-benefit analysis of these agents in the treatment of ADHF requires a well-designed prospective study.
  Books and Chapters
  • Cheung RJ and Gupta EK. New Therapies in Dyslipidemia. In: Dong BJ, Elliott DP, eds. Ambulatory Care Self-Assessment Program, 2014 Book 2. Cardiology Care. Lenexa, KS: American College of Clinical Pharmacy, 2014: 34-60.

    ( 9/2014 )
  • Heart failure chapter of Rx Prep Course Book – A Comprehensive Course for the NAPLEX & CPJE (13th edition), Rx Prep, Inc.

    ( 0/2013 )
  Abstract
  • Wong S, Ocampo N, Cheung R, & Chiong J. (2011). Aggressive Diuresis as a Predictor of Hospital Readmission Due to Acute Heart Failure Exacerbations in Elderly Patients. Journal of Cardiac Failure, 17(8), S79-S79. ( 8/2011 - Present )